FindTrial
Sign In

Analysis of the relationship between compliance and curative effect of Vinecra in the treatment of acute myeloid leukemia

Analysis of the relationship between compliance and curative effect of Vinecra in the treatment of acute myeloid leukemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076788
Enrollment
Unknown
Registered
2023-10-18
Start date
2023-10-20
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia

Interventions

The group with good compliance and the group with poor compliance were taken orally:None

Sponsors

The First Affiliated Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) AML patients with oral Venekra. Diagnostic criteria refer to the 2021 edition of the Chinese Clinical Oncology Society (csco) guidance; (2) Age 18-85 years old; (3) The physical fitness score of the Eastern Cancer Collaboration Group (ECOG) was 0-3. Life expectancy > 8 weeks;

Exclusion criteria

Exclusion criteria: (1) Previous history of myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and other diseases; (2) Patients who cannot understand and follow the study protocol; (3) Patients with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Medication compliance;—

Secondary

MeasureTime frame
security;Total effective rate;—

Countries

China

Contacts

Public ContactHongBin Xu

The First Affiliated Hospital of Ningbo University

jiang_rh@126.com+86 189 5178 3095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026